Cochlear Ltd. on Wednesday projected its full-year FY26 cash flow to double, signaling robust operational performance despite expected margin compression.
The Australian hearing implant manufacturer attributed the cash flow improvement to sustained demand for its core cochlear implant devices and ancillary hearing solutions. Revenue growth, driven by global adoption of its latest implant models, underpinned the outlook, though management warned of margin headwinds from elevated supply chain costs and intensified competition in key markets.
Operating margins are forecast to decline year-on-year as pricing pressures in the U.S. and Europe offset gains from volume increases. Cochlear’s gross margin is expected to narrow due to higher raw material and logistics expenses, while operating expenses remain elevated amid investments in research and development and commercial expansion.
Cash flow from operations is projected to reach A$1.2 billion for FY26, up from A$600 million in FY25, reflecting strong conversion of revenue into liquidity. The company reaffirmed its dividend policy, maintaining a payout ratio target of 50-60% of underlying profit, though the timing of distributions will depend on cash flow stability.
Analysts noted that while margin pressures are a near-term concern, Cochlear’s market leadership in hearing solutions and recurring revenue from implant maintenance contracts provide a buffer against volatility. The company’s focus on premium pricing in high-margin segments, such as its latest implant platforms, may help mitigate some of the competitive pressures.
Cochlear’s FY26 outlook was disclosed in investor presentation materials released ahead of its full-year results, scheduled for release in August. The company did not provide specific revenue or profit guidance, citing macroeconomic uncertainty and regulatory risks in its core markets.
Shares in Cochlear were little changed in early trading, reflecting a market that had already priced in moderate margin expectations. The stock has gained approximately 12% over the past 12 months, outperforming the broader Australian healthcare sector.
